Sign In
Buy AXGN
$40.63
+1.17 (+2.97%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement
11:35am, Friday, 17'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 16.)
Abbott Laboratories (...
Stocks That Hit 52-Week Lows On Thursday
02:28pm, Thursday, 16'th Apr 2020
During Thursday's morning session, 33 stocks hit new 52-week lows.
Significant Points:
America Movil (NYSE: AMX) was the largest, in terms of market cap, to set a...
The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant
12:09pm, Thursday, 16'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 15.)
Bio-Rad Laboratories,...
Exchange Traded Concepts LLC Acquires 7,738 Shares of AxoGen, Inc (NASDAQ:AXGN)
10:14am, Thursday, 16'th Apr 2020
Exchange Traded Concepts LLC grew its holdings in shares of AxoGen, Inc (NASDAQ:AXGN) by 135.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exc
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
11:00am, Wednesday, 15'th Apr 2020
Axogen, Inc. (AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2020 fi
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
11:00am, Wednesday, 15'th Apr 2020
ALACHUA, Fla., April 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions...
AxoGen, Inc (NASDAQ:AXGN) Shares Sold by UBS Asset Management Americas Inc.
10:20am, Monday, 13'th Apr 2020
UBS Asset Management Americas Inc. reduced its position in AxoGen, Inc (NASDAQ:AXGN) by 11.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. T
Is AxoGen, Inc.'s (NASDAQ:AXGN) CEO Being Overpaid?
01:21pm, Sunday, 12'th Apr 2020
Karen Zaderej has been the CEO of AxoGen, Inc. (NASDAQ:AXGN) since 2011. This analysis aims first to contrast CEO...
Macquarie Group Ltd. Sells 3,665 Shares of AxoGen, Inc (NASDAQ:AXGN)
10:22am, Sunday, 12'th Apr 2020
Macquarie Group Ltd. cut its holdings in AxoGen, Inc (NASDAQ:AXGN) by 5.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm ow
BidaskClub Downgrades AxoGen (NASDAQ:AXGN) to Sell
08:58am, Saturday, 11'th Apr 2020
AxoGen (NASDAQ:AXGN) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports. Several other equi
Contrasting Stereotaxis (OTCMKTS:STXS) & AxoGen (OTCMKTS:AXGN)
07:18am, Saturday, 11'th Apr 2020
AxoGen (NASDAQ:AXGN) and Stereotaxis (OTCMKTS:STXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividen
Credit Suisse AG Reduces Stake in AxoGen, Inc (NASDAQ:AXGN)
10:24am, Wednesday, 08'th Apr 2020
Credit Suisse AG lowered its stake in shares of AxoGen, Inc (NASDAQ:AXGN) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
Bank of New York Mellon Corp Sells 121,520 Shares of AxoGen, Inc (NASDAQ:AXGN)
09:30am, Wednesday, 08'th Apr 2020
Bank of New York Mellon Corp reduced its stake in AxoGen, Inc (NASDAQ:AXGN) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange
AxoGen (NASDAQ:AXGN) versus SpectraScience (NASDAQ:SCIE) Financial Review
06:18am, Wednesday, 08'th Apr 2020
AxoGen (NASDAQ:AXGN) and SpectraScience (OTCMKTS:SCIE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings,
